Moran George W, Kurtzman Jane T, Carpenter Christina P
Department of Urology, Columbia University Irving Medical Center, New York, NY, USA.
Department of Urology, Columbia University Irving Medical Center, New York, NY, USA.
J Pediatr Urol. 2022 Oct;18(5):598-608. doi: 10.1016/j.jpurol.2022.08.015. Epub 2022 Aug 20.
The use of barrier layers between the neourethra and skin is associated with lower rates of post-operative urethrocutaneous fistula (UCF) following hypospadias surgery. Recent studies have evaluated the ability of biologic adjuvant urethral coverings (BAUCs) - namely acellular matrix (AM), tissue adhesives (TAs), and autologous platelet-rich plasma or fibrin (PRP/PRF) - to prevent wound complications following hypospadias surgery. In general, however, these studies are small and conducted at single institutions.
To assess the effect of BAUCs on the rate of UCF following single-stage primary hypospadias repair.
We conducted a systematic review of studies reporting the rate of postoperative UCF in pediatric patients undergoing single-stage, primary hypospadias repairs using either AM, TA, or PRP/PRF as a layer interposed between the neourethra and skin. We then performed a pooled proportional meta-analysis of post-operative UCF. Patients within each study who underwent comparable surgery but did not receive a BAUC were used as controls.
10 studies were included in our review. The meta-analysis included 280 patients from 7 studies who underwent hypospadias repairs with BAUCs. The pooled incidence of UCF was 10% (95% CI 6-14%). Mean follow-up ranged 5-23.5 months in the 5/7 studies reporting specific durations, and ≥6 month and 14-30 months, respectively, in the other two studies. Patients in whom a BAUC was used had significantly lower odds of UCF than control patients (OR 0.39, 95% CI 0.24-0.64, p = 0.0002). In subgroup analyses, significant superiority held for AM and TA; proximal or penoscrotal cases; transverse preputial island flap (TPIF) technique; when both cases and controls had local flaps; and when neither cases nor controls had flaps.
The use of BAUCs was associated with decreased rates of post-operative UCF in single-stage primary hypospadias repairs and may be most beneficial in more severe cases and when used in addition to local flaps or when using a flap is not possible. In 2/3 studies of PRP/PRF and 2/4 studies of tubularized incised plate (TIP) technique, dartos flaps were used in controls but not BAUC patients, which may explain the lack of benefit demonstrated for these subgroups. This meta-analysis is limited by the quality of evidence in the included studies, which are not uniformly randomized. Furthermore, the follow-up durations and methods for assessing complications are not standardized between included studies.
The meta-analysis herein suggests that using BAUCs may reduce UCF rates following hypospadias surgery. Rigorous prospective evaluation is needed to validate this benefit.
在尿道下裂手术中,在新尿道和皮肤之间使用屏障层可降低术后尿道皮肤瘘(UCF)的发生率。最近的研究评估了生物辅助尿道覆盖物(BAUCs)——即脱细胞基质(AM)、组织粘合剂(TAs)以及自体富血小板血浆或纤维蛋白(PRP/PRF)——预防尿道下裂手术后伤口并发症的能力。然而,总体而言,这些研究规模较小且是在单一机构进行的。
评估BAUCs对一期原发性尿道下裂修复术后UCF发生率的影响。
我们对报告了使用AM、TA或PRP/PRF作为新尿道和皮肤之间的一层进行一期原发性尿道下裂修复的儿科患者术后UCF发生率的研究进行了系统评价。然后我们对术后UCF进行了汇总比例荟萃分析。将每项研究中接受了类似手术但未接受BAUC的患者用作对照。
我们的评价纳入了10项研究。荟萃分析纳入了来自7项研究的280例接受了使用BAUCs进行尿道下裂修复的患者。UCF的汇总发生率为10%(95%CI 6 - 14%)。在报告了具体随访时长的5/7项研究中,平均随访时间为5 - 23.5个月,另外两项研究中的随访时间分别≥6个月和14 - 30个月。使用BAUCs的患者发生UCF的几率显著低于对照患者(OR 0.39,95%CI 0.24 - 0.64,p = 0.0002)。在亚组分析中,AM和TA、近端或阴茎阴囊型病例、横向包皮岛状皮瓣(TPIF)技术、病例组和对照组均采用局部皮瓣时以及病例组和对照组均未采用皮瓣时具有显著优势。
在一期原发性尿道下裂修复中使用BAUCs与术后UCF发生率降低相关,并且在更严重的病例中以及与局部皮瓣联合使用时或无法使用皮瓣时可能最为有益。在PRP/PRF的2/3项研究和管状切开板(TIP)技术的2/4项研究中,对照组使用了肉膜皮瓣而BAUCs组未使用,这可能解释了这些亚组未显示出益处的原因。本荟萃分析受到纳入研究证据质量的限制,这些研究并非均为随机研究。此外,纳入研究之间的随访时长和并发症评估方法并不统一。
本文的荟萃分析表明,使用BAUCs可能降低尿道下裂手术后的UCF发生率。需要进行严格的前瞻性评估来验证这一益处。